Citi analyst Samantha Semenkow maintains $BioAge Labs (BIOA.US)$ with a buy rating, and maintains the target price at $45.
According to TipRanks data, the analyst has a success rate of 38.8% and a total average return of -8.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $BioAge Labs (BIOA.US)$'s main analysts recently are as follows:
BioAge Labs, a clinical-stage biotech specializing in therapies for metabolic diseases, has captured the attention due to its lead asset, azelaprag, which is an oral, small molecule agonist of the apelin receptor being developed to target obesity. The company's prospects are seen positively in light of the upcoming STRIDES readout, bolstered by azelaprag's oral administration, ease of manufacture, and strong preclinical data that suggest a promising clinical profile for treating obesity.
Initial findings indicate that BioAge Labs' azelaprag has shown promise, potentially enhancing weight loss when used alongside GLP-1s, and may also contribute to improved body composition and the quality of weight loss. Early data suggest that azelaprag not only contributes to weight reduction but also has a positive impact on muscle.
BioAge Labs, a clinical stage biotech specializing in metabolic diseases, is noted for its leading drug Azelaprag, which has a unique mechanism that mimics exercise, targeting obesity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
